EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma

Zhiyu Pang, Yupeng Wang, Zhaorui Liu, Shan Zhang, Chong Wei, Zhuofan Xu, Ziqian Wang, Hongyun Chen, Jie Liu, Wei Zhang

JAMA Dermatology · 01.09.2025 · 161 (9) · 923

DOI: 10.1001/jamadermatol.2025.1926 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift JAMA Dermatology, erschienen am 01.09.2025. Verfasst von Zhiyu Pang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medica…. Hauptthemen laut MEDLINE: Aminopyridines, Lymphoma, T-Cell, Cutaneous, Antineoplastic Combined Chemotherapy Protocols, Benzamides. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Patients with relapsed or refractory (r/r) cutaneous T-cell lymphoma (CTCL) have limited treatment options. Combining agents that target complementary oncogenic pathways may enhance efficacy while maintaining tolerability.

Objective

To evaluate the safety and efficacy of linperlisib, a PI3Kδ inhibitor, combined with chidamide, a histone deacetylase inhibitor, in patients with r/r CTCL. Design, Setting, and Participants This prospective, single-arm, phase 1 nonrandomized clinical trial with a 3 + 3 dose-escalation phase followed by dose expansion was conducted at a tertiary referral hospital in China from May 1, 2023, to March 6, 2025, with a median follow-up of 8.9 months (range, 1-21 months). It included patients with histologically confirmed advanced CTCL. All had an Eastern Cooperative Oncology Group performance status of 0 to 2 and received a median (range) of 3 (1-7) prior systemic therapies. Patients were enrolled consecutively based on eligibility.

Interventions

Oral linperlisib administered once daily in escalating doses (40 mg, 60 mg, or 80 mg) plus chidamide, 20 mg, twice weekly. Treatment continued until progression, unacceptable toxic effects, or withdrawal. Main Outcomes and Measures Primary outcomes were dose-limiting toxic effects, maximum tolerated dose, and objective response rate. Secondary outcomes included safety, progression-free survival, and disease control rate.

Results

Of 22 patients (19 [86.4%] with mycosis fungoides, 3 [13.6%] with Sézary syndrome), 10 were female individuals (45.5%), and the median (range) age was 44 (27-71) years. No dose-limiting toxic effects were observed. The recommended phase 2 dose of linperlisib was 80 mg. The most common treatment-related adverse events were nausea (8 [36.4%]), pruritus (7 [31.8%]), and skin rash (6 [27.3%]), mostly grade 1 to 2. Grade 3 adverse events occurred in 5 patients (22.7%); no grade 4 to 5 events were reported. The objective response rate was 59.1% (13 of 22; 95% CI, 38.7%-76.7%), including 2 complete responses and 11 partial responses. The disease control rate was 86.4% (19 of 22), and the median progression-free survival was 5.4 months. Conclusions and Relevance This nonrandomized clinical trial found that plus chidamide showed a manageable safety profile and promising activity in r/r CTCL. This all-oral combination may represent a new therapeutic option for advanced CTCL, particularly in mycosis fungoides. Trial Registration ClinicalTrials.gov Identifier: NCT06037239

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesLymphoma, T-Cell, CutaneousAntineoplastic Combined Chemotherapy ProtocolsBenzamidesSkin NeoplasmsNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedAdultProspective StudiesHistone Deacetylase InhibitorsDose-Response Relationship, DrugMaximum Tolerated DoseTreatment OutcomeDrug Resistance, NeoplasmChinaProgression-Free Survival

Substanzen

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideAminopyridinesBenzamidesHistone Deacetylase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Researc…
  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Tsinghua Medicine, School of Medicine, Tsinghua University, Beijing, China.

Zitieren

APA

Pang, Z., Wang, Y., Liu, Z., Zhang, S., Wei, C., Xu, Z., Wang, Z., Chen, H., Liu, J., & Zhang, W. (2025). Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma. JAMA Dermatology, 161(9), 923. https://doi.org/10.1001/jamadermatol.2025.1926

Vancouver

Pang Z, Wang Y, Liu Z, Zhang S, Wei C, Xu Z, et al. Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma. JAMA Dermatology. 2025;161(9):923. doi:10.1001/jamadermatol.2025.1926

BibTeX
@article{Pang2025,
  author = {Pang, Zhiyu and Wang, Yupeng and Liu, Zhaorui and Zhang, Shan and Wei, Chong and Xu, Zhuofan and Wang, Ziqian and Chen, Hongyun and Liu, Jie and Zhang, Wei},
  title = {Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma},
  journal = {JAMA Dermatology},
  year = {2025},
  volume = {161},
  number = {9},
  pages = {923},
  doi = {10.1001/jamadermatol.2025.1926}
}
Kostenlos starten →